Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS

Trial Profile

Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms REFALS
  • Sponsors Orion; Orion Pharma
  • Most Recent Events

    • 22 Apr 2021 Results assessing how clinical chemistry measurements from the REFALS trial correlate with amyotrophic lateral sclerosis disease course to elucidate their potential as biomarkers of disease, presented at the 73rd Annual Meeting of the American Academy of Neurology.
    • 22 Apr 2021 Results assessing the association of baseline characteristics with response to levosimendan in people with amyotrophic lateral sclerosis (ALS), were presented at the 73rd Annual Meeting of the American Academy of Neurology.
    • 09 Oct 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top